

# Marco Trevisan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6978314/publications.pdf>

Version: 2024-02-01

35  
papers

819  
citations

567281

15  
h-index

580821

25  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1201  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 153-161.	2.9	6
2	Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. American Heart Journal, 2022, 243, 177-186.	2.7	19
3	Reply to the letter regarding the article "Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care"™. European Journal of Heart Failure, 2022, 24, 399-400.	7.1	0
4	MO514: Cardiorenal Outcomes Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
5	Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function. European Heart Journal, 2021, 42, 1476-1485.	2.2	26
6	Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults. Neurology, 2021, 96, .	1.1	50
7	MO493 PATTERNS OF HYPERKALEMIA AND ASSOCIATED ADVERSE HEALTH OUTCOMES IN PERSONS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
8	MO129 COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
9	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. ELife, 2021, 10, .	6.0	21
10	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. European Journal of Heart Failure, 2021, 23, 1698-1707.	7.1	37
11	Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them. CKJ: Clinical Kidney Journal, 2021, 14, 1317-1326.	2.9	31
12	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 104-111.	3.0	23
13	Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design. CKJ: Clinical Kidney Journal, 2021, 14, 1307-1316.	2.9	4
14	Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREATinine Measurement project. Nephrology Dialysis Transplantation, 2020, 35, 1894-1900.	0.7	10
15	Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrology Dialysis Transplantation, 2020, 35, 1518-1526.	0.7	62
16	Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREATinine Measurement project. Nephrology Dialysis Transplantation, 2020, 35, 1908-1915.	0.7	14
17	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 167-175.	3.0	12
18	Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm <scp>CREATinine</scp> Measurements (<scp>SCREAM</scp>) project. European Journal of Heart Failure, 2020, 22, 1790-1799.	7.1	21

#	ARTICLE	IF	CITATIONS
19	Kidney function and the risk of heart failure in patients with new-onset atrial fibrillation. <i>International Journal of Cardiology</i> , 2020, 320, 101-105.	1.7	4
20	P0774 KIDNEY FUNCTION, KIDNEY FUNCTION DECLINE AND THE RISK OF ALL CAUSE, VASCULAR AND ALZHEIMER'S DEMENTIA: THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
21	Bisphosphonate utilization across the spectrum of eGFR. <i>Archives of Osteoporosis</i> , 2020, 15, 69.	2.4	4
22	P0771 STOPPING MINERALOCORTICOID RECEPTOR ANTAGONISTS AFTER HYPERKALEMIA AND RISK OF ADVERSE OUTCOMES IN PATIENTS WITH HEART FAILURE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
23	MO073 ACCELERATION OF KIDNEY FUNCTION DECLINE AFTER INCIDENT HOSPITALIZATION WITH CARDIOVASCULAR DISEASE: THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
24	Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1336-1345.	4.5	22
25	Kidney Dysfunction and the Risk of Developing Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 305-314.	2.8	59
26	Estimated GFR and Hospital-Acquired Infections Following Major Surgery. <i>American Journal of Kidney Diseases</i> , 2019, 73, 11-20.	1.9	14
27	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 65-76.	4.1	62
28	Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1217-1226.	7.1	116
29	FP341 PLASMA POTASSIUM AND THE RISK OF MORTALITY: A TIME-DEPENDENT ANALYSIS FROM THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i146-i146.	0.7	0
30	SP330 AEGFR AND THE RISK OF CANCER: THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i455-i455.	0.7	0
31	SaO024 INCIDENCE, PREDICTORS AND CLINICAL MANAGEMENT OF HYPERKALEMIA IN NEW USERS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i325-i325.	0.7	0
32	Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction. <i>American Heart Journal</i> , 2018, 205, 53-62.	2.7	10
33	Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1314-1320.	4.5	45
34	A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 267-273.	4.0	26
35	Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. <i>Gastroenterology</i> , 2017, 153, 702-710.	1.3	121